ATNM (Actinium Pharmaceuticals) Ending Cash Position: $36.81 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATNM Actinium Pharmaceuticals Inc ATNM
17 GF Score
Price $1.12
! 4 Warning Signs
View Full Analysis

What is Actinium Pharmaceuticals Ending Cash Position?

Actinium Pharmaceuticals ATNM -0.88% 17 Ending Cash Position is $36.81 Mil as of Jun. 2026. GuruFocus rates ATNM with a GF Score™ of 17/100. The stock has 4 warning signs investors should review.

Actinium Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2026 was $36.81 Mil.

Actinium Pharmaceuticals's quarterly Ending Cash Position declined from Dec. 2025 ($48.33 Mil) to Mar. 2026 ($42.47 Mil) and declined from Mar. 2026 ($42.47 Mil) to Jun. 2026 ($36.81 Mil).

Actinium Pharmaceuticals's annual Ending Cash Position declined from Dec. 2023 ($76.99 Mil) to Dec. 2024 ($73.23 Mil) and declined from Dec. 2024 ($73.23 Mil) to Dec. 2025 ($48.33 Mil).

Actinium Pharmaceuticals Ending Cash Position Related Terms

Actinium Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Actinium Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actinium Pharmaceuticals Ending Cash Position Chart

Actinium Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 78.22 109.61 76.99 73.23 48.33

Actinium Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.26 53.72 48.33 42.47 36.81
ATNM
17GF Score
Actinium Pharmaceuticals Inc ATNM
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actinium Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Actinium Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=73.228+-24.895
=48.33

Actinium Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=42.469+-5.657
=36.81

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $36.81 Mil mean?
Actinium Pharmaceuticals (ATNM) has a Ending Cash Position of $36.81 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Actinium Pharmaceuticals and its competitors.
Is Actinium Pharmaceuticals' Ending Cash Position too high?
Actinium Pharmaceuticals' current Ending Cash Position is $36.81 Mil. Overall, Actinium Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Actinium Pharmaceuticals' Ending Cash Position compare to PSTV and IGC?
Actinium Pharmaceuticals' Ending Cash Position of $36.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Actinium Pharmaceuticals and its competitors. Actinium Pharmaceuticals's current Ending Cash Position is $36.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinium Pharmaceuticals stock overvalued right now?
Actinium Pharmaceuticals (ATNM) has a current Ending Cash Position of $36.81 Mil. The current Ending Cash Position is $36.81 Mil. Actinium Pharmaceuticals' overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Actinium Pharmaceuticals (ATNM), the current Ending Cash Position is $36.81 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actinium Pharmaceuticals Business Description

Other Exchanges 7AY1:Germany
Address 100 Park Avenue, 23rd Floor, New York, NY, USA, 10017
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
17GF Score

Get the complete analysis for ATNM

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12
Price